The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Dravet syndrome is a rare genetic epileptic disorder that is due to a brain dysfunction. It usually begins in the first year of an otherwise healthy infant and remains throughout life.

Dravet syndrome is difficult to treat and has a poor long-term prognosis. Complications of the disease often contribute to a poor quality of life for patients and their caregivers.

People who have Dravet syndrome, a rare and severe form of epilepsy, usually experience their first seizure within the first year of life. (1) These early seizures, which are typically triggered ...

Dravet syndrome, a rare and severe form of epilepsy, affects approximately 1 in 15,700 children. It is primarily caused by mutations in the SCN1A gene, which is crucial for regulating brain activity.

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

DUBLIN--(BUSINESS WIRE)--The "Dravet Syndrome Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This report outlays comprehensive insights of present ...

Dravet syndrome is a type of epilepsy that starts during a child's first year. If your child has this condition, they might have seizures that last for several minutes at a time.

Dravet syndrome is a rare, severe form of epilepsy with symptoms that begin before a child turns 15 months old (and often within the first year of life). (1) Formerly known as severe myoclonic ...